127 related articles for article (PubMed ID: 35421568)
21. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
22. Relationship between neurokinin-1 receptor and substance P in the striatum: light and electron microscopic immunohistochemical study in the rat.
Li JL; Wang D; Kaneko T; Shigemoto R; Nomura S; Mizuno N
J Comp Neurol; 2000 Mar; 418(2):156-63. PubMed ID: 10701441
[TBL] [Abstract][Full Text] [Related]
23. Effect of peptidases on the ability of exogenous and endogenous neurokinins to produce neurokinin 1 receptor internalization in the rat spinal cord.
Marvizon JC; Wang X; Lao LJ; Song B
Br J Pharmacol; 2003 Dec; 140(8):1389-98. PubMed ID: 14623771
[TBL] [Abstract][Full Text] [Related]
24. Regulated norepinephrine transporter interaction with the neurokinin-1 receptor establishes transporter subcellular localization.
Arapulisamy O; Mannangatti P; Jayanthi LD
J Biol Chem; 2013 Oct; 288(40):28599-610. PubMed ID: 23979140
[TBL] [Abstract][Full Text] [Related]
25. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke.
Turner RJ; Helps SC; Thornton E; Vink R
Brain Res; 2011 Jun; 1393():84-90. PubMed ID: 21466790
[TBL] [Abstract][Full Text] [Related]
26. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Akazawa T; Kwatra SG; Goldsmith LE; Richardson MD; Cox EA; Sampson JH; Kwatra MM
J Neurochem; 2009 May; 109(4):1079-86. PubMed ID: 19519779
[TBL] [Abstract][Full Text] [Related]
27. Substance P and the neurokinin-1 receptor expression in dog ileum with and without inflammation.
Polidoro G; Giancola F; Fracassi F; Pietra M; Bettini G; Asti M; Chiocchetti R
Res Vet Sci; 2017 Oct; 114():297-307. PubMed ID: 28628846
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin 1 receptor internalization in spinal cord slices induced by dorsal root stimulation is mediated by NMDA receptors.
Marvizón JC; Martínez V; Grady EF; Bunnett NW; Mayer EA
J Neurosci; 1997 Nov; 17(21):8129-36. PubMed ID: 9334388
[TBL] [Abstract][Full Text] [Related]
29. Substance P release and neurokinin 1 receptor activation in the rat spinal cord increase with the firing frequency of C-fibers.
Adelson D; Lao L; Zhang G; Kim W; Marvizón JC
Neuroscience; 2009 Jun; 161(2):538-53. PubMed ID: 19336248
[TBL] [Abstract][Full Text] [Related]
30. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
[TBL] [Abstract][Full Text] [Related]
31. Substance P activates both contractile and inflammatory pathways in lymphatics through the neurokinin receptors NK1R and NK3R.
Chakraborty S; Nepiyushchikh Z; Davis MJ; Zawieja DC; Muthuchamy M
Microcirculation; 2011 Jan; 18(1):24-35. PubMed ID: 21166923
[TBL] [Abstract][Full Text] [Related]
32. Substance P-induced trafficking of beta-arrestins. The role of beta-arrestins in endocytosis of the neurokinin-1 receptor.
McConalogue K; Déry O; Lovett M; Wong H; Walsh JH; Grady EF; Bunnett NW
J Biol Chem; 1999 Jun; 274(23):16257-68. PubMed ID: 10347182
[TBL] [Abstract][Full Text] [Related]
33. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor.
Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD
Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645
[TBL] [Abstract][Full Text] [Related]
34. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Thornton E; Vink R
PLoS One; 2012; 7(4):e34138. PubMed ID: 22485158
[TBL] [Abstract][Full Text] [Related]
35. Role of neurogenic substance P in overexpression of alveolar macrophages' neurokinin 1 receptor in mice exposed to cigarette smoke.
Xu J; Xu F
Exp Lung Res; 2010 May; 36(4):243-54. PubMed ID: 20426532
[TBL] [Abstract][Full Text] [Related]
36. Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor.
MacLeod AM; Merchant KJ; Brookfield F; Kelleher F; Stevenson G; Owens AP; Swain CJ; Casiceri MA; Sadowski S; Ber E
J Med Chem; 1994 Apr; 37(9):1269-74. PubMed ID: 7513763
[TBL] [Abstract][Full Text] [Related]
37. N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats.
Fernandes J; Mudgal J; Rao CM; Arora D; Basu Mallik S; Pai KSR; Nampoothiri M
Toxicol Mech Methods; 2018 Jun; 28(5):328-334. PubMed ID: 29185389
[TBL] [Abstract][Full Text] [Related]
38. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
39. Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus.
Lacoste B; Riad M; Descarries L
Eur J Neurosci; 2006 Jun; 23(11):2947-58. PubMed ID: 16819984
[TBL] [Abstract][Full Text] [Related]
40. Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis.
Douglas SD; Lai JP; Tuluc F; Schwartz L; Kilpatrick LE
Ann N Y Acad Sci; 2008 Nov; 1144():90-6. PubMed ID: 19076368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
